Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14192603 | 0.84 | KCNH2 (0.45) | KCNH2USP30KEAP1NFE2L2FYN | |
| SCHEMBL5114288 | 0.80 | KCNH2 (0.79) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5112511 | 0.76 | KCNH2 (1.00) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5111576 | 0.67 | KCNH2 (0.56) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL7060974 | 0.64 | ALDH1A1 (0.59) | — | |
| SCHEMBL7062322 | 0.62 | ALDH1A1 (0.60) | — | |
| Oxalic Acid SCHEMBL9369813 | 0.62 | KCNH2 (0.41) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5420773 | 0.61 | HRH3 (0.44) | USP30HRH3FYNSMN1; SMN2ADORA2A | |
| SCHEMBL5420770 | 0.61 | HRH3 (0.44) | USP30HRH3FYNSMN1; SMN2ADORA2A | |
| SCHEMBL5420767 | 0.61 | HRH3 (0.44) | USP30HRH3FYNSMN1; SMN2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | claimed |
| EP-1831212-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006065217-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | KCNH2 501/4885USP30 4245/4885TLR9 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.